Titan Pharmaceuticals Inc

Titan Pharmaceuticals — Investor Presentation (July 2014)

21 slides from Titan Pharmaceuticals's investor presentation, Jul 21, 2014

  1. Slide 1: Corporate Presentation July 2014

    1 Corporate Presentation July 2014

  2. Slide 2: Safe Harbor

    2 The presentation may contain “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Reference is made in particular to the description of our plans and objectives for future operations, assumptions unde

  3. Slide 3: Titan Pharmaceuticals Overview

    3 Titan Pharmaceuticals Overview Titan Pharmaceuticals is a specialty pharmaceutical company focused on developing innovative treatments for chronic conditions based on its proprietary long - term drug delivery platform, ProNeura ™ • Probuphine ® : A long acting formulation of buprenorphine for the

  4. Slide 4: Probuphine: Highlights

    4 Probuphine : Highlights Probuphine is expected to be the first long acting buprenorphine product on the market for the treatment of opioid dependence • Probuphine provides six month sustained release of buprenorphine, a drug already on the market as a daily dosed sublingual tablet/film • Expanding

  5. Slide 5: Opioid Dependence - Viewed as an Epidemic

    5 Recognized as an epidemic by the federal government • Opioid dependence is recognized by the government as a medical epidemic that warrants immediate and significant resource allocation • NIDA (part of NIH) provided a $7.6 million grant (2010 - 2011) in support of Probuphine development Sources: E

  6. Slide 6: Opioid Dependence - Disease Overview

    6 • Addiction is a primary, chronic disease of brain reward, motivation, memory and related neurobiological circuitry* • Inability to consistently abstain • Impairment in behavioral control • Craving • Diminished recognition of significant problems with one’s behaviors • Addiction involves cycles of

  7. Slide 7: Opioid Dependence - Treatment Overview

    7 • In the U.S. buprenorphine has replaced methadone as the gold standard in treating opioid dependence • Buprenorphine is a mixed partial agonist at the mu receptor and an antagonist at the kappa receptor • Ceiling effect • Improved safety profile • Lack of euphoria Ceiling Effect of Buprenorphine

  8. Slide 8: Opioid Dependence - Expanding Market

    8 • Daily buprenorphine is the current gold standard • U.S. sales of daily oral formulations of buprenorphine ( Suboxone ®) exceeded $1.4B in 2012 • U.S. buprenorphine prescriptions have far outstripped those of methadone since 2006 • Challenges with oral buprenorphine • Compliance • Fluctuating lev

  9. Slide 9: Probuphine: Active Buprenorphine Along with Inert EVA Polymer

    9 EVA polymer Buprenorphine Blended & Extruded 26 mm long, 2.5 mm diameter Each implant contains 80 mg of buprenorphine HCl which has been blended and extruded with ethylene vinyl acetate (EVA) co - polymer Probuphine is a subdermal implant capable of delivering continuous and persistent around the

  10. Slide 10: Probuphine Clinical Summary

    10 • Six clinical studies completed to date with final Phase 3 study under way • Small dose finding study • Two well - controlled safety and efficacy studies showing clinical and statistical superiority over placebo and non - inferiority to Suboxone published in Journal of American Medical Associati

  11. Slide 11: Final Phase 3 Study Design

    11 Pro - 814 Study Design: Follow - up 24 Weeks (Weeks 1 to 24) Monthly Visits Group A : Daily SL BPN ≤ 8 mg 4 placebo implants Screening R Clinically stable, Daily ≤ 8 mg SL BPN for at least 90 days, Opioid - negative urine toxicology for last 90 days Maintenance Phase 2 Weeks (25 to 26) Up to 2 We

  12. Slide 12: Target Patient Profile

    12 Initial market research indicates that physicians would recommend Probuphine across wide patient population • Patients stabilized on buprenorphine therapy – Serious and committed patients with good treatment history • Patients that have a high relapse history – Patients with treatment compliance

  13. Slide 13: Probuphine Value Proposition

    13 Efficacy Effective in reducing illicit opioid use Enhanced compliance may lead to superior outcomes Safety Lower drug exposure may provide superior safety and tolerability Ease of Use Unique delivery system dosed once every six months Continuous buprenorphine delivery • Non - fluctuating blood le

  14. Slide 14: Potential for the Treatment of Chronic Pain

    14 • Buprenorphine has several advantages over other opioids used for chronic pain • Safer than other opioids – Ceiling effect for respiratory depression, relatively long half - life, minimal euphoric effect • Buprenorphine transdermal patch (3 - 7 days) is approved in U.S., Europe and Australia for

  15. Slide 15: Titan: Adding Value Beyond Probuphine

    15 Titan: Adding Value Beyond Probuphine Proprietary ProNeura Technology Platform • Novel long - term drug delivery technology providing around - the - clock medication over periods of six months to a year clinically validated through the Probuphine program • Applicable to other chronic treatments w

  16. Slide 16: Parkinson's Disease Overview

    16 Parkinson’s Disease Overview Parkinson’s Disease • Parkinson’s disease (PD) is characterized by the loss of dopaminergic neurons which leads to increasing activity in the brain region which influences movement and motor function Treatment • Early - stage PD patients are treated with drugs designe

  17. Slide 17: Parkinson's Disease: Treated Population Increasing Worldwide

    17 Parkinson’s Disease: Treated Population Increasing Worldwide 17 Based on information from Titan and other sources believed to be reliable and prepared exclusively for Titan. Woodside Capita l P artners is not responsible for any use that Titan may make of this material.

  18. Slide 18: Parkinson's Disease: Therapeutics Market

    18 Parkinson’s Disease: Therapeutics Market Source: GlobalData Sales for PD in the US by Drug Class 2012 – 2022 Year Total PD Sales % DA $ DA 2012 $1.1 bn 26% 286m 2022 $2.3bn 18% 414m About 1.5 million people in the U.S. have Parkinson’s disease according to the Parkinson’s Disease Foundation. The

  19. Slide 19: ProNeura – Parkinson's Disease Program

    19 ProNeura – Parkinson’s Disease Program • Non - clinical Proof of Concept • E valuation of ProNeura technology in MPTP Parkinsonian monkey model • Ropinirole (Requip ® ), a dopamine agonist marketed by GSK in the US for PD, was safely and continuously delivered from ProNeura - ropinirole implants

  20. Slide 20: Titan Pharmaceuticals Summary

    20 Titan Pharmaceuticals is a specialty pharmaceutical company focused on developing innovative treatments for chronic conditions based on its proprietary long - term drug delivery platform, ProNeura™ • Probuphine, a long - acting controlled - release buprenorphine product for opioid dependence • Gr

  21. Slide 21: Marc Rubin, M.D.

    21 Marc Rubin, M.D. July 30, 2008

Titan Pharmaceuticals — Investor Presentation (July 2014) on 6ix